Agomab Therapeutics director David R. Epstein reports acquisition of $88,800 in common shares
AGMB•Agomab Therapeutics director David R. Epstein purchased 10,000 common shares for a total of $88,800, increasing his direct holdings to 25,000 shares.
1. Share purchases
Epstein purchased 5,000 shares at $8.86 each and 5,000 at $8.90 each, bringing his direct holdings to 25,000 shares.
